Solid biosciences announces pricing of underwritten offering

Charlestown, mass., feb. 18, 2025 (globe newswire) -- solid biosciences inc. (nasdaq: sldb) (the “company” or “solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced the pricing of an underwritten offering of 35,739,810 shares of its common stock at an offering price of $4.03 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 13,888,340 shares of common stock at an offering price of $4.029 per pre-funded warrant. the aggregate gross proceeds of the offering are expected to be approximately $200.0 million, before deducting underwriting discounts and commissions and other offering expenses. each pre-funded warrant will have an exercise price of $0.001 per share, will be exercisable immediately and will be exercisable until all of the pre-funded warrants are exercised in full. all of the securities in the offering are being sold by solid. the offering is expected to close on or about february 19, 2025, subject to the satisfaction of customary closing conditions.
SLDB Ratings Summary
SLDB Quant Ranking